Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen’s neuroscience pipeline stretches from multiple-sclerosis blockbusters to cutting-edge Alzheimer’s candidates, and the disclosures that follow are equally dense. If you’ve tried to spot pipeline milestones, patent cliffs, or R&D spend buried inside a 200-page filing, you know the challenge. Stock Titan turns that complexity into clarity by delivering Biogen SEC filings explained simply, in real time.
Our AI-powered summaries break down each Biogen annual report 10-K simplified, flagging segment revenue, drug concentration risk, and collaboration economics. Dig into a Biogen quarterly earnings report 10-Q filing without paging through footnotes—the platform highlights inventory swings, clinical-trial costs, and cash burn in seconds. Material updates like FDA decisions arrive as Biogen 8-K material events explained, so you never miss a catalyst.
The dashboard also tracks Biogen insider trading Form 4 transactions. Receive Biogen Form 4 insider transactions real-time to monitor Biogen executive stock transactions Form 4 before market open. Curious about leadership pay? The Biogen proxy statement executive compensation section is distilled into an easy-to-scan table. Whether you’re stress-testing valuation models or searching “How to read Biogen’s 10-K annual report?”, our AI delivers Biogen earnings report filing analysis that answers what professionals actually ask.
- Set keyword alerts for Leqembi, Spinraza, or biosimilar launches
- Compare quarter-over-quarter R&D trends instantly
- Export footnote-level data for financial models
Start understanding Biogen SEC documents with AI and spend minutes—not hours—finding what drives BIIB.
Sean Godbout, identified as a Director and the issuer's Chief Accounting Officer, reported changes in his beneficial ownership of BioGen Inc. (BIIB) on
Priya Singhal, Head of Development at Biogen Inc. (BIIB), reported a series of equity transactions dated 08/29/2025 and 09/02/2025. A grant of 1,669 restricted stock units (RSUs) vested (recorded as an acquisition at $0) increasing her beneficial ownership before sales to 7,096.1428 shares. On 08/29/2025 she sold 807 shares at $132.22 and on 09/02/2025 she sold 517 shares at $133.55, leaving her with 5,772.1428 shares following the reported transactions. The filing notes the RSU award was granted on September 1, 2022 and vests in three equal annual installments.
Biogen Inc. (BIIB) has filed a Form 144 notifying a proposed sale of 517 shares of common stock through Fidelity Brokerage Services. The filing lists an aggregate market value of $69,045.35 for the shares and states an approximate sale date of 09/02/2025 on NASDAQ. The shares were acquired on 09/01/2025 by restricted stock vesting from the issuer and payment is listed as compensation.
The filing shows 146,614,598 shares outstanding for the issuer. No securities sold in the past three months are reported and the filer represents there is no undisclosed material adverse information. The notice identifies Fidelity Brokerage Services LLC as the broker and includes the standard certification and signature/representation language required by Rule 144.
Biogen held its 2025 Annual Meeting of Stockholders on June 17, 2025, with three key matters put to vote. All eleven nominated directors were successfully elected to serve one-year terms until the 2026 annual meeting, with notable strong support for Lloyd Minor, Menelas Pangalos, and Monish Patolawala, each receiving over 114 million votes in favor.
Key voting outcomes include:
- Independent Auditor Appointment: PricewaterhouseCoopers LLP was ratified as the independent auditor for FY2025 with strong support (120,065,433 votes in favor)
- Say-on-Pay Vote: The executive compensation package was approved, though with more divided support - 78.5 million votes in favor versus 37.1 million against
The relatively split vote on executive compensation (67.8% approval) suggests some shareholder concerns about leadership remuneration. The high broker non-votes (10.2 million) across most items indicate significant holdings by institutional investors who did not provide voting instructions.
Form 4 overview: On 06/17/2025 Biogen (BIIB) director Menelas N. Pangalos received 2,370 restricted stock units (RSUs) at no cost. The units convert to common stock on the earlier of the company’s next annual meeting or 06/17/2026. After the award, the director beneficially owns 2,370 BIIB shares directly.
No shares were sold or disposed of; the filing reflects standard director compensation. Given Biogen’s large share count, the issuance is immaterial to dilution or valuation and therefore neutral for investors.
FAQ
What is the current stock price of Biogen (BIIB)?
What is the market cap of Biogen (BIIB)?
